|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.51 USD | +0.18% |
|
-2.30% | -20.40% |
| Apr. 13 | Jefferies Initiates Veracyte at Buy With $45 Price Target | MT |
| Mar. 16 | Veracyte names Kevin Haas as chief development and technology officer | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 220M | 297M | 361M | 446M | 517M | |||||
Total Revenues | 220M | 297M | 361M | 446M | 517M | |||||
Cost of Goods Sold, Total | 74.4M | 102M | 113M | 136M | 144M | |||||
Gross Profit | 145M | 195M | 248M | 310M | 373M | |||||
Selling General & Admin Expenses, Total | 158M | 171M | 192M | 199M | 226M | |||||
R&D Expenses | 29.84M | 40.6M | 53.8M | 69.29M | 70.81M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 15.98M | 21.35M | 20.57M | 14.85M | 13.15M | |||||
Other Operating Expenses, Total | 204M | 233M | 266M | 283M | 310M | |||||
Operating Income | -58.99M | -37.63M | -17.93M | 26.78M | 62.99M | |||||
Interest Expense, Total | -241K | -198K | -15K | -2K | -1K | |||||
Interest And Investment Income | 135K | 1.97M | 7.34M | 11.15M | 12.72M | |||||
Net Interest Expenses | -106K | 1.77M | 7.33M | 11.15M | 12.72M | |||||
Currency Exchange Gains (Loss) | -1.08M | 197K | 723K | -2.04M | 3.97M | |||||
Other Non Operating Income (Expenses) | 1.44M | 2.68M | 1.13M | 495K | 436K | |||||
EBT, Excl. Unusual Items | -58.74M | -32.97M | -8.75M | 36.38M | 80.12M | |||||
Merger & Related Restructuring Charges | -22.1M | - | - | -5.1M | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | -6.71M | |||||
Asset Writedown | - | -3.3M | -68.35M | -3.37M | -20.5M | |||||
Other Unusual Items | -810K | -154K | 483K | -2.17M | 15.3M | |||||
EBT, Incl. Unusual Items | -81.65M | -36.43M | -76.61M | 25.74M | 68.2M | |||||
Income Tax Expense | -6.09M | 133K | -2.21M | 1.61M | 1.85M | |||||
Earnings From Continuing Operations | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | |||||
Net Income to Company | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | |||||
Net Income - (IS) | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | |||||
Net Income to Common Incl Extra Items | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | |||||
Net Income to Common Excl. Extra Items | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.11 | -0.51 | -1.02 | 0.32 | 0.84 | |||||
Basic EPS - Continuing Operations | -1.11 | -0.51 | -1.02 | 0.32 | 0.84 | |||||
Basic Weighted Average Shares Outstanding | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M | |||||
Net EPS - Diluted | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 | |||||
Diluted EPS - Continuing Operations | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 | |||||
Diluted Weighted Average Shares Outstanding | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M | |||||
Normalized Basic EPS | -0.54 | -0.29 | -0.08 | 0.3 | 0.64 | |||||
Normalized Diluted EPS | -0.54 | -0.29 | -0.08 | 0.29 | 0.62 | |||||
Supplemental Items | ||||||||||
EBITDA | -39.4M | -11.7M | 9.26M | 50.24M | 84.4M | |||||
EBITA | -43.01M | -16.27M | 2.64M | 41.58M | 76.19M | |||||
EBIT | -58.99M | -37.63M | -17.93M | 26.78M | 62.99M | |||||
EBITDAR | -34.34M | -5.88M | 17.37M | 60.67M | 103M | |||||
Total Revenues (As Reported) | 220M | 297M | 361M | 446M | 517M | |||||
Effective Tax Rate - (Ratio) | 7.45 | -0.37 | 2.88 | 6.24 | 2.71 | |||||
Current Domestic Taxes | 63K | 426K | 1.52M | 1.81M | 2.31M | |||||
Current Foreign Taxes | 54K | 134K | 193K | 22K | 114K | |||||
Total Current Taxes | 117K | 560K | 1.71M | 1.84M | 2.43M | |||||
Deferred Domestic Taxes | -4.03M | 118K | -90K | -230K | -580K | |||||
Deferred Foreign Taxes | -2.17M | -545K | -3.83M | - | - | |||||
Total Deferred Taxes | -6.2M | -427K | -3.92M | -230K | -580K | |||||
Normalized Net Income | -36.71M | -20.61M | -5.47M | 22.74M | 50.07M | |||||
Interest on Long-Term Debt | 241K | 198K | 15K | 2K | 1K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Marketing Expenses | 7.21M | 6.14M | 5.42M | 6.28M | 5.56M | |||||
Selling and Marketing Expenses | 79.84M | 97.56M | 101M | 95.43M | 100M | |||||
General and Administrative Expenses | 78.44M | 67.25M | 82.1M | 92.9M | 115M | |||||
Research And Development Expense From Footnotes | 29.84M | 43.9M | 57.3M | 69.29M | 70.81M | |||||
Net Rental Expense, Total | 5.06M | 5.82M | 8.11M | 10.44M | 19.03M | |||||
Imputed Operating Lease Interest Expense | 614K | 533K | 69.89K | 5.26K | 3.35K | |||||
Imputed Operating Lease Depreciation | 4.44M | 5.28M | 8.04M | 10.43M | 19.03M | |||||
Stock-Based Comp., COGS (Total) | 640K | 1.05M | 1.78M | 2.32M | 2.29M | |||||
Stock-Based Comp., R&D Exp. (Total) | 4.64M | 6M | 5.28M | 7.51M | 7.92M | |||||
Stock-Based Comp., S&M Exp. (Total) | 4.39M | 5.94M | 9.59M | 6.9M | 8.32M | |||||
Stock-Based Comp., G&A Exp. (Total) | 12.85M | 13.74M | 16.5M | 19.52M | 25.08M | |||||
Total Stock-Based Compensation | 22.52M | 26.73M | 33.14M | 36.25M | 43.6M |
- Stock Market
- Equities
- VCYT Stock
- Financials Veracyte, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















